Literature DB >> 19325145

Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.

Anne G Semb1, Thor Ueland, Pål Aukrust, Nicholas J Wareham, Robert Luben, Lars Gullestad, John J P Kastelein, Kay-Tee Khaw, S Matthijs Boekholdt.   

Abstract

OBJECTIVE: The purpose of this study was to examine the association between serum levels of osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) and future coronary artery disease (CAD) in apparently healthy individuals. The identification of OPG as a novel cardiovascular risk marker suggests an association between mediators of bone homeostasis and cardiovascular disease. METHODS AND
RESULTS: Serum levels of OPG and RANKL were analyzed in a prospective case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) study, a cohort study of 25 663 men and women, where 951 apparently healthy individuals who developed a coronary event during 6 years' follow-up were matched by sex and age with 1705 healthy controls. Baseline OPG, but not RANKL, was higher in cases than in controls, and OPG was higher in women than in men. Both men and women in the highest OPG quartile had a higher risk for future CAD. These associations were independent of established cardiovascular risk factors, and when using OPG as a continuous variable, also after adjustment for CRP. In contrast, RANKL showed no association with coronary events.
CONCLUSIONS: OPG is associated with the risk of future CAD in apparently healthy men and women, independent of established cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19325145     DOI: 10.1161/ATVBAHA.109.184101

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  22 in total

1.  Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls.

Authors:  I G Poornima; K Shields; L H Kuller; S M Manzi; R Ramsey-Goldman; C Richardson; E Rhew; D D Dunlop; J Song; D Edmundowicz; G T Kondos; J J Carr; C B Langman; H Price; A H Chung; L B Santelices; R H Mackey
Journal:  Lupus       Date:  2018-01-01       Impact factor: 2.911

2.  Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.

Authors:  Jiajia Xia; Linman Li; Wei Ren; Xiaoya Zheng; Chan Liu; Jinchao Li; Tingying Chen; Xiaofeng Li; Lingli Wang; Yumei Hu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Authors:  Wolfgang Lieb; Philimon Gona; Martin G Larson; Joseph M Massaro; Izabella Lipinska; John F Keaney; Jian Rong; Diane Corey; Udo Hoffmann; Caroline S Fox; Ramachandran S Vasan; Emelia J Benjamin; Christopher J O'Donnell; Sekar Kathiresan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

4.  Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease.

Authors:  Julia J Scialla; Mary B Leonard; Raymond R Townsend; Lawrence Appel; Myles Wolf; Matt J Budoff; Jing Chen; Eva Lustigova; Crystal A Gadegbeku; Melanie Glenn; Asaf Hanish; Dominic Raj; Sylvia E Rosas; Stephen L Seliger; Matthew R Weir; Rulan S Parekh
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

5.  Osteoprotegerin levels in patients with severe mental disorders.

Authors:  Sigrun Hope; Ingrid Melle; Pål Aukrust; Ingrid Agartz; Steinar Lorentzen; Nils Eiel Steen; Srdjan Djurovic; Thor Ueland; Ole A Andreassen
Journal:  J Psychiatry Neurosci       Date:  2010-09       Impact factor: 6.186

6.  Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension.

Authors:  Karolina Czerwińska; Małgorzata Poręba; Adam Prokopowicz; Lidia Januszewska; Aleksandra Jaremków; Iwona Markiewicz-Górka; Helena Martynowicz; Grzegorz Mazur; Rafał Poręba; Krystyna Pawlas; Paweł Gać
Journal:  Cardiovasc Toxicol       Date:  2022-04-12       Impact factor: 3.231

7.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.

Authors:  Stefan Kiechl; Jürgen Wittmann; Andrea Giaccari; Michael Knoflach; Peter Willeit; Aline Bozec; Alexander R Moschen; Giovanna Muscogiuri; Gian Pio Sorice; Trayana Kireva; Monika Summerer; Stefan Wirtz; Julia Luther; Dirk Mielenz; Ulrike Billmeier; Georg Egger; Agnes Mayr; Friedrich Oberhollenzer; Florian Kronenberg; Michael Orthofer; Josef M Penninger; James B Meigs; Enzo Bonora; Herbert Tilg; Johann Willeit; Georg Schett
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

8.  Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.

Authors:  Constantinos Giaginis; Aikaterini Papadopouli; Athina Zira; Athanasios Katsargyris; Christos Klonaris; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2012-10

9.  Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links.

Authors:  A Fisher; W Srikusalanukul; M Davis; P Smith
Journal:  Clin Interv Aging       Date:  2013-02-25       Impact factor: 4.458

10.  Osteoprotegerin as a marker of atherosclerosis in diabetic patients.

Authors:  Areti Augoulea; Nikolaos Vrachnis; Irene Lambrinoudaki; Konstantinos Dafopoulos; Zoe Iliodromiti; Angelos Daniilidis; Michail Varras; Andreas Alexandrou; Efthymios Deligeoroglou; George Creatsas
Journal:  Int J Endocrinol       Date:  2013-01-17       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.